Inari Medical, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2022 and for the Full Year 2023
January 10, 2023 at 08:00 am EST
Share
Inari Medical, Inc. provided preliminary revenue guidance for the fourth quarter and full year 2022 and for the full year 2023. For the quarter, the company expects Preliminary unaudited revenue to be between $107.0 million and $108.0 million, up 12% sequentially and 29% year-over-year (at the midpoint of the range).
For the full year 2022, the company expects preliminary unaudited revenue to be between $382.7 million and $383.7 million, up approximately 38% over the full year 2021 (at the midpoint of the range).
For the full year 2023, the company expects revenue of $470 million to $480 million, reflecting growth of approximately 23% to 25% over 2022.
Inari Medical, Inc. is a medical device company. The Companyâs products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
INARI MEDICAL, INC. 
